VERLINGUE
12.12.2022 09:01:41 CET | Business Wire | Press release
The Adelaïde Group subsidiary and corporate protection specialist Verlingue is overhauling its visual identity and embracing a brand service promise to buoy its European ambitions.
Verlingue achieved a turnover of €211.6 million in 2021, up 11.9%, of which 27% outside France, and announced the acquisition of a new broker in Portugal, RT Global Insurance.
A new identity rolled out simultaneously in France, Great Britain, Switzerland and Portugal to uphold its ambitions of becoming a leading independent insurance broker on a European scale
Spurred on by plans to deepen its European foothold, Verlingue is making changes to its brand platform to accentuate its uniqueness and uphold its new tagline: “Protecting today. Imagining tomorrow”.
The broker hopes to shine a light on both its model’s stability and ambitions. In a world where new and emerging risks are multiplying, Verlingue embraces forward-looking risk management, helping clients manage any potential constraints on their activities, drive growth and improve overall performance.
Verlingue continues expanding across Europe with a new acquisition in Portugal
Two years to the day after acquiring Luso Atlantica, Verlingue acquires RT Global Insurance, a company specialized in P&C, which is set to generate growth of 15% for Verlingue Portugal.
“We want to remain an independent and family-owned company, a trusted partner while expanding across France and abroad, being ambitious while offering an alternative compared to more global or finance-led names. Today we are taking a step forward in our objective to build an attractive project for the teams who decide to join our adventure and to build a large European insurance broker,” notes Jacques Verlingue, Chairman of the Adelaïde Group.
Drawing on identity, values and unique expertise in becoming one of Europe’s leading independent insurance brokers
At the dawn of its 90th anniversary, Verlingue is continuing to take a long-term approach in becoming a major European, family-owned and independent insurance broker.
Ever faithful to the Impact 24 strategic plan, the Adelaïde Group is confirming its ambitions to hit sales of €400M to €500M through profitable organic growth and strategic European acquisitions focused on industrial interest.
About Verlingue
An insurance broker specializing in corporate protection, Verlingue is a subsidiary of the Adelaïde Group working alongside entrepreneurs.
With offices in France, Great Britain, Switzerland and Portugal, and through partners in over 100 countries, Verlingue works with its clients over the long term and at all times to better understand and anticipate new and emerging risks in order to develop simple and effective solutions to protect their business (corporate risk) and staff (employee benefits and pensions).
1,200 employees, 400 of whom are based outside France
€2.2B in premiums negotiated on behalf of its clients
24 offices in Europe
LinkedIn / www.verlingue.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005107/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom